EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing SGLT2 inhibitors: Treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin

Ruben J Overduin iD, Sarah C Grünert iD, Martine T P Besouw iD, Mathieu S Bolhuis iD, Joost Groen iD, Andrea B Schreuder iD, Mathias Woidy iD, Simona Murko iD, René Santer iD, Terry G J Derks iD

Journal of Inherited Metabolic Disease · 2024-09 · 47 (5) · 1018-1027

DOI: 10.1002/jimd.12752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 27.05.2024. Verfasst von Ruben J Overduin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlan…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Sodium-Glucose Transporter 2 Inhibitors, Fanconi Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal proximal tubulopathy in Fanconi‐Bickel syndrome is caused by impaired basolateral glucose transport via GLUT2 and consequently, intracellular accumulation of glucose and glycogen. SGLT2 inhibitors act on apical glucose reabsorption of renal proximal tubular cells. The purpose of this study was to retrospectively describe the first experiences with repurposing the SGLT2 inhibitor empagliflozin to treat the generalized tubulopathy in Fanconi‐Bickel syndrome. A case series was conducted of seven persons from five families (five males, two females; three children, who were 14y5m, 2y9m, and 1y6m old) with genetically confirmed Fanconi‐Bickel syndrome, off‐label treated with empagliflozin. Median (range) age at start of empagliflozin was 27 years (1y6m – 61y) and duration of follow‐up under empagliflozin treatment was 169 days (57–344). Under empagliflozin (up to 25 mg/d), biochemical parameters of tubular cell integrity (urinary N ‐acetyl‐glucosaminidase) and/or tubular functions (including urinary α1‐microglobulin) improved in all persons with Fanconi‐Bickel syndrome, albeit to varying degrees. Clinically, supplementations (i.e., phosphate, alkali, carnitine, and alfacalcidol) could be completely discontinued in the three children, whereas results in the four adult patients were more variable and not as significant. Empagliflozin was well‐tolerated and no symptomatic hypoglycemia was observed. In conclusion, SGLT2 inhibitors such as empagliflozin shift the metabolic block in Fanconi‐Bickel syndrome, that is, they intervene specifically in the underlying pathophysiology and can thus attenuate renal proximal tubulopathy, especially when started in early childhood.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 InhibitorsFanconi SyndromeDrug RepositioningHumansMaleFemaleAdultRetrospective StudiesAdolescentMiddle AgedKidney Tubules, ProximalChildChild, PreschoolInfantYoung Adult

Stichwörter der Autor:innen

Fanconi‐Bickel syndromeSGLT2 inhibitordrug repurposinginherited metabolic diseaseoff‐label treatmentrenal proximal tubulopathy

Substanzen

empagliflozinBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of General Pediatrics, Adolescent Medicine and Neonatology, University Medical Center Freiburg, Faculty of Medicine, Freiburg, Germany.
  • Department of Pediatric Nephrology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Laboratory Medicine University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Pediatrics, University Medical Center Eppendorf, Hamburg, Germany.

ORCID-Profile: Ruben J Overduin, Sarah C Grünert, Martine T P Besouw, Mathieu S Bolhuis, Joost Groen, Andrea B Schreuder, Mathias Woidy, Simona Murko, René Santer, Terry G J Derks

Zitieren

APA

Overduin, R. J., Grünert, S. C., Besouw, M. T. P., Bolhuis, M. S., Groen, J., Schreuder, A. B., Woidy, M., Murko, S., Santer, R., & Derks, T. G. J. (2024). Repurposing SGLT2 inhibitors: Treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin. Journal of Inherited Metabolic Disease, 47(5), 1018-1027. https://doi.org/10.1002/jimd.12752

Vancouver

Overduin RJ, Grünert SC, Besouw MTP, Bolhuis MS, Groen J, Schreuder AB, et al. Repurposing SGLT2 inhibitors: Treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin. Journal of Inherited Metabolic Disease. 2024;47(5):1018-1027. doi:10.1002/jimd.12752

BibTeX
@article{Overduin2024,
  author = {Overduin, Ruben J and Grünert, Sarah C and Besouw, Martine T P and Bolhuis, Mathieu S and Groen, Joost and Schreuder, Andrea B and Woidy, Mathias and Murko, Simona and Santer, René and Derks, Terry G J},
  title = {Repurposing SGLT2 inhibitors: Treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2024},
  volume = {47},
  number = {5},
  pages = {1018--1027},
  doi = {10.1002/jimd.12752}
}
Kostenlos starten →